Ticlopidine is a first generation thienopyridine ADP/P2Y12 receptor inhibitor that exhibits antithrombotic and cardioprotective activities. Ticlopidine binds to the P2Y12 receptor, preventing changes in the glycoprotein IIb/IIIa conformation and suppressing fibrinogen-platelet binding. This compound is clinically used to treat acute coronary syndrome and myocardial infarction.
| Cas No. | 53885-35-1 |
|---|---|
| Purity | ≥98% |
| Formula | C14H14ClNS • HCl |
| Formula Wt. | 300.25 |
| Chemical Name | 5-[(2-Chlorophenyl)-methyl]4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride |
| IUPAC Name | 5-[(2-chlorophenyl)methyl]-6,7-dihydro-4H-thieno[3,2-c]pyridine;hydrochloride |
| Synonym | Panaldine; TIclid; Ticlodix; Ticlodone; Caudaline |
| Melting Point | 190°C |
| Solubility | Soluble in ethanol, methanol or chloroform. |
| Appearance | White Crystal Powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | T3310 MSDS PDF |
|---|---|
| Info Sheet | T3310 Info Sheet PDF |
Cohen MV, Downey JM. Combined cardioprotectant and antithrombotic actions of platelet P2Y12 receptor antagonists in acute coronary syndrome: just what the doctor ordered. J Cardiovasc Pharmacol Ther. 2014 Mar;19(2):179-90. PMID: 24298192.
Secco GG, Parisi R, Mirabella F, et al. P2Y12 inhibitors: pharmacologic mechanism and clinical relevance. Cardiovasc Hematol Agents Med Chem. 2013 Jun;11(2):101-5. PMID: 22963529.
